EP1860442A3 - Neurosteroids as markers for Alzheimer's disease - Google Patents

Neurosteroids as markers for Alzheimer's disease Download PDF

Info

Publication number
EP1860442A3
EP1860442A3 EP07075646A EP07075646A EP1860442A3 EP 1860442 A3 EP1860442 A3 EP 1860442A3 EP 07075646 A EP07075646 A EP 07075646A EP 07075646 A EP07075646 A EP 07075646A EP 1860442 A3 EP1860442 A3 EP 1860442A3
Authority
EP
European Patent Office
Prior art keywords
tissue
test sample
fluid
dhea
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07075646A
Other languages
German (de)
French (fr)
Other versions
EP1860442A2 (en
Inventor
Vassilios Papadopoulos
Rachel C. Brown
Caterina Cascio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgetown University
Original Assignee
Georgetown University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgetown University filed Critical Georgetown University
Priority claimed from EP01903310A external-priority patent/EP1254251B1/en
Publication of EP1860442A2 publication Critical patent/EP1860442A2/en
Publication of EP1860442A3 publication Critical patent/EP1860442A3/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Abstract

A method of detecting oxidative stress-mediated Dehydroepiandrosterone (DHEA) formation in a test sample of human blood, body fluid or tissue comprising:
(a) treating said test fluid or tissue with an agent that produces oxidative metabolites in a control fluid or tissue, wherein the agent is selected from the group consisting of FeSO4, other Fenton reactants, and oxido-reducing agents,
(b) treating a control fluid or tissue with said agent, and
(c) determining whether the quantities of DHEA in the test sample and in the control sample rise in response to said treatment,

whereby a lack of response in the test sample relative to the control sample indicates that oxidative stress-mediated DHEA formation occurred previously in said test sample of body fluid.
EP07075646A 2000-01-28 2001-01-26 Neurosteroids as markers for Alzheimer's disease Withdrawn EP1860442A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17869800P 2000-01-28 2000-01-28
EP01903310A EP1254251B1 (en) 2000-01-28 2001-01-26 Neurosteroids as markers for alzheimer's disease

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP01903310A Division EP1254251B1 (en) 2000-01-28 2001-01-26 Neurosteroids as markers for alzheimer's disease

Publications (2)

Publication Number Publication Date
EP1860442A2 EP1860442A2 (en) 2007-11-28
EP1860442A3 true EP1860442A3 (en) 2008-07-09

Family

ID=38621934

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07075646A Withdrawn EP1860442A3 (en) 2000-01-28 2001-01-26 Neurosteroids as markers for Alzheimer's disease

Country Status (1)

Country Link
EP (1) EP1860442A3 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162198A (en) * 1991-02-08 1992-11-10 Virginia Commonwealth University Method of using dehydroepiandrosterone and dehydroepiandrosterone-sulfate as inhibitors of thrombuxane production and platelet aggregation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162198A (en) * 1991-02-08 1992-11-10 Virginia Commonwealth University Method of using dehydroepiandrosterone and dehydroepiandrosterone-sulfate as inhibitors of thrombuxane production and platelet aggregation

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AISEN P S ET AL: "GLUCOCORTICOIDS IN ALZHEIMER'S DISEASE THE STORY SO FAR", DRUGS AND AGING, ADIS INTERNATIONAL LTD, NZ, vol. 12, no. 1, January 1998 (1998-01-01), pages 1 - 6, XP001079609, ISSN: 1170-229X *
BROWN RACHEL C ET AL: "Oxidative stress-mediated DHEA formation in Alzheimer's disease pathology.", NEUROBIOLOGY OF AGING, vol. 24, no. 1, 2003, pages 57 - 65, XP002280553, ISSN: 0197-4580 *
CASCIO C ET AL: "Detection of P450c17-independent pathways for dehydroepiandrosterone (DHEA) biosynthesis in brain glial tumor cells", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 95, no. 6, 17 March 1998 (1998-03-17), March 17, 1998, pages 2862 - 2867, XP002280552, ISSN: 0027-8424 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1996, YANASE TOSHIHIKO ET AL: "Serum dehydroepiandrosterone (DHEA) and DHEA-sulfate (DHEA-S) in Alzheimer's disease and in cerebrovascular dementia", XP002280554, Database accession no. PREV199698779408 *
ENDOCRINE JOURNAL, vol. 43, no. 1, 1996, pages 119 - 123, ISSN: 0918-8959 *
PRASAD V V K ET AL: "Precursors of the neurosteroids", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 91, no. 8, 1994, pages 3220 - 3223, XP002462540, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
EP1860442A2 (en) 2007-11-28

Similar Documents

Publication Publication Date Title
AU617706B2 (en) A device for preventing involuntary micturition
WO1996040054A3 (en) Intraurethral pharmacotherapy of incontinence
AU2002227184A1 (en) Methods for development and use of diagnostic and therapeutic agents
WO2002072172A3 (en) Apparatus and methods for capture of medical agents
WO1999046279A3 (en) INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE
WO2004087018A3 (en) Double ended intravascular medical device
AU4176101A (en) Universal catheter anchoring system
AU2002216273A1 (en) Proteins, genes and their use for diagnosis and treatment of kidney response
ATE269740T1 (en) RIGHT Atrium INTRODUCTION DEVICE SYSTEM
CA2072914A1 (en) Method for reducing malodor in absorbent products and products formed thereby
SE9501777L (en) Device for maintaining passage of urine through the prostate gland
AU7205398A (en) An adhesive agent and use of such adhesive agent
BR0103256A (en) Use of biochemical substances for a composition for the prevention and treatment of health conditions caused by constriction of smooth muscle cells in organs of the human body
WO2000018954A3 (en) Use of pex in the treatment of metabolic bone diseases
WO2002000210A3 (en) Use of agents capable of reducing uric acid levels for the treatment of cardiovascular disease
AU2002220803A1 (en) Composition, in particular cosmetic, containing 7-hydroxy dhea and/or 7-keto dhea and at least an isoflavonoid
CA2221900A1 (en) Use of trospium chloride and 2-component system for the same
WO2002009735A3 (en) Methods and devices to modulate the wound response
EP1162457A3 (en) Multiple coagulation test system and method of using a multiple coagulation test system
EP1860442A3 (en) Neurosteroids as markers for Alzheimer's disease
DE69906745D1 (en) SWELLABLE ABSORBENT PRODUCT AND METHOD FOR THE PRODUCTION THEREOF
EP2202241A3 (en) Therapeutic compounds and methods for modulating V3, a versican isoform
EP0958835A4 (en) Preventive/remedy for frequent urination and urinary incontinence
AU2001237543A1 (en) Proteins, genes and their use for diagnosis and treatment of schizophrenia
GB2370507B (en) Apparatus for the diagnosis and therapy of neuro-muscular and other tissue disorders

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 1254251

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: CASCIO, CATERINA

Inventor name: BROWN, RACHEL C.

Inventor name: PAPADOPOULOS, VASSILIOS

AKX Designation fees paid

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090112